ADNA

Advanced Diagnostics and New therapeutic Approaches

ADNA est accrédité par Lyonbiopôle

Identity card

Global budget: 202 263 k€

Public funding: 89514 k€

Public funders: Oséo / BPI France (except FUI)

Call for projects: ISI Oséo

Year start: 2007

Completed project


Accredited by the French competitiveness cluster Lyonbiopôle

More information: http://www.institut-merieux.com/projetssante_adna.php


Strategic business area: Human Medicines, In vitro Diagnostic, Medical Technologies

Application fields: Genetic / Rare diseases, Infectious diseases, Inflammatory diseases, Oncology

Technological approaches / Keywords: Bioinformatics / Software, Biomanufacturing, Immunotherapy, Innovative formulation, Vector vaccine

Stage of development at the beginning of the project: Basic research, Discovery, Preclinical development

Abstract

  The ADNA program seeks to develop a more personalized form of medicine, focusing on infectious diseases, cancers and rare genetic diseases by providing innovative ‘theranostic” products and services for healthcare professionals. With the support of Institut Mérieux, the ADNA program brings together 9 partners : bioMerieux, CEA-Leti, CNRS, Genethon, GenoSafe, HCL, ST-Microelectronics, Transgene, and UCB Lyon1. The program intends to identify, validate biomarkers for providing diagnostic and therapeutic solution to healthcare needs which are not currently addressed efficiently.


Objectives

  Based on the observation that specific genetic factors determine how each individual patient responds to treatment, the objective is to develop products that can be used to better diagnose diseases or predict patient response, so that a tailored treatment program can be devised, providing better care to patients.


Innovative assets
Highlights
Actual results
Perspectives

Innovative assets

ADNA program combines innovative assets for each partner: - Genethon will test on patients the first therapy genetic treatment produced in “Généthon bioProd”, the largest bioproduction facility in Europe (this site is not part of the ADNA program and was not granted by OSEO/BPI). - Transgene aims, with TG4010, to propose a therapeutic vaccine associated with two companion tests, combining immunology and cell sorting technologies. - BioMerieux innovates in bioMarkers field, especially in sepsis and liver cancer, associated with new technologies as Mass spectrometry or New generation sequencing.

En poursuivant votre navigation sur notre site, vous acceptez l'utilisation des cookies et la collecte de vos données et informations personnelles par Lyonbiopôle, dans les finalités de mesurer le trafic sur le site Web, de fournir des statistiques et de vous proposer des contenus adaptés à vos centres d’intérets. Pour exercer vos droits d'accès, de rectification, d'opposition, de suppression et de portabilité, conformément au règlement général sur la protection des données (UE n°2016/679), vous etes informés que vous pouvez envoyer votre demande à dpo@lyonbiopole.com. Plus de détails sont disponibles en cliquant ici J'accepte